Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Leslie Wilbanks

Neurology Munster, IN Medical Doctor

NPI 1154550994 CMS profile 1136632

801 MacArthur Blvd Ste 404, Munster, IN 46321

Open in the dashboard

General payments

$2,410

91 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leslie Wilbanks of Munster, IN is reported in the CMS Open Payments database as having received $2,410 across 91 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $676 16
2024 General $915 40
2023 General $161 8
2022 General $214 12
2021 General $24 1
2020 General $61 3
2019 General $359 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leslie Wilbanks
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Leslie Wilbanks were reported at $676. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Leslie Wilbanks Neurology median Middle half National median
2019 $359 $474 $118–$2,177 $163
2020 $61 $367 $82–$2,309 $114
2021 $24 $438 $104–$2,547 $132
2022 $214 $442 $103–$2,388 $149
2023 $161 $464 $119–$2,312 $160
2024 $915 $468 $119–$2,323 $164
2025 $676 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $474 30 payments
  2. Jazz Pharmaceuticals Inc. $358 12 payments
  3. Catalyst Pharmaceuticals, Inc. $222 3 payments
  4. Pfizer Inc. $162 8 payments
  5. Microtransponder, Inc. $162 1 payment
  6. Janssen Scientific Affairs, LLC $149 1 payment
  7. W. L. Gore & Associates, Inc. $138 1 payment
  8. Biogen, Inc. $108 4 payments
  9. US WorldMeds, LLC $74 4 payments
  10. Sunovion Pharmaceuticals Inc. $72 3 payments
  11. Other $492 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,410 91 payments
Products named General payments · program years 2019–2025
  1. QULIPTA $247 16 payments
  2. Epidiolex $186 7 payments
  3. XYWAV $172 5 payments
  4. NURTEC ODT $162 8 payments
  5. UBRELVY $155 8 payments
  6. CARDIOFORM Septal Occluder $138 1 payment
  7. ZAVZPRET $115 6 payments
  8. TYSABRI $108 4 payments
  9. FIRDAPSE $91 2 payments
  10. VUMERITY $88 3 payments
  11. Other $960 52 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

587

Median for Neurology: 833

Drug cost

$1,320,233

Median for Neurology: $202,670

Branded share of claims

22.7%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Soliris Eculizumab Brand 13 $682,738
Octagam Immun Globg(Igg)/Malt/Iga Ov50 Brand 13 $347,904
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 15 $266,157
Emgality Pen Galcanezumab-Gnlm Brand 11 $9,032
Pyridostigmine Bromide Generic 21 $2,449
Zolmitriptan Generic 11 $1,796
Carbamazepine Er Carbamazepine Brand 11 $1,298
Pregabalin Generic 41 $1,259
Mycophenolate Mofetil Generic 24 $1,251
Gabapentin Generic 106 $1,219

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$65,939

Medicare's payments for the services billed

Medicare patients

380

Average age 74

Services billed

814

232 women, 148 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 71%
Ischemic heart disease 47%
Diabetes 44%
Heart failure 43%
Chronic kidney disease 42%
Depression 39%
Atrial fibrillation 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $212
$212 — —
Epidiolex
  • JAZZ PHARMACEUTICALS INC. $105
$105 — —
FIRDAPSE
  • CATALYST PHARMACEUTICALS, INC. $77
$77 — —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $66
$66 — —
VYEPTI
  • Lundbeck LLC $63
$63 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

91 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record